<p>Clearside Biomedical（纳斯达克代码：CLSD - 获取免费报告）的股票在 Needham &amp; Company LLC 发布的一份报告中重申了 “买入” 评级，Benzinga 报道。它们目前对该股票的目标价为 4.00 美元。Needham &amp; Company LLC 的目标价意味着该股票相较于之前的收盘价有 373.20% 的潜在上涨空间。</p>
<p>获取 <strong>Clearside Biomedical</strong> 的提醒：</p>
<p>CLSD 已经成为其他多份报告的主题。HC Wainwright 在 3 月 31 日的研究报告中重申了 “买入” 评级，并对 Clearside Biomedical 的股票设定了 6.00 美元的目标价。StockNews.com 在 3 月 18 日的研究报告中将 Clearside Biomedical 的股票评级从 “持有” 下调至 “卖出”。最后，Chardan Capital 在 3 月 28 日的报告中重申了 “买入” 评级，并对 Clearside Biomedical 的股票设定了 6.00 美元的目标价。一位分析师对该股票给予了卖出评级，而四位分析师则给予了买入评级。根据 MarketBeat.com 的数据，Clearside Biomedical 目前的共识评级为 “适度买入”，平均目标价为 5.25 美元。</p>
<p><strong>查看我们最新的 CLSD 股票报告</strong></p>
<h2>Clearside Biomedical 股票表现</h2>
<p>CLSD 的股票在周二开盘价为 0.85 美元。Clearside Biomedical 的 1 年最低价为 0.77 美元，1 年最高价为 1.65 美元。该股票的市值为 6521 万美元，市盈率为-1.88，贝塔系数为 2.04。公司的 50 日移动平均线为 0.96 美元，200 日移动平均线为 1.03 美元。</p>
<p>Clearside Biomedical（纳斯达克代码：CLSD - 获取免费报告）最近在 3 月 27 日发布了季度财报。该公司报告每股收益（EPS）为-0.10 美元，超出市场共识预期的-0.13 美元，超出幅度为 0.03 美元。该公司本季度的收入为 31 万美元，而分析师预期为 27 万美元。卖方分析师预测 Clearside Biomedical 在当前年度的每股收益将为-0.48 美元。</p>
<h2>对 Clearside Biomedical 的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近调整了对该公司的持股。投资者 Fiduciary Advisor Network LLC 在第四季度收购了 Clearside Biomedical 的新股份，价值约为 32,000 美元。Northern Trust Corp 在第四季度将其在 Clearside Biomedical 的持股增加了 24.0%。Northern Trust Corp 目前拥有 165,499 股该公司的股票，价值 157,000 美元，此前在上个季度又购买了 32,048 股。最后，Geode Capital Management LLC 在第四季度将其在 Clearside Biomedical 的股份增加了 4.5%。Geode Capital Management LLC 目前拥有 764,058 股该公司的股票，价值 726,000 美元，此前在该期间又购买了 32,672 股。机构投资者和对冲基金持有该公司 18.75% 的股份。</p>
<h2>Clearside Biomedical 公司简介</h2>
<p>（获取免费报告）</p>
<p>Clearside Biomedical, Inc 是一家生物制药公司，专注于通过脉络膜上腔革命性地输送治疗药物到眼后部。它提供 XIPERE，一种用于治疗葡萄膜炎性黄斑水肿的三氟氯噻吨脉络膜上腔注射悬液。它还开发 CLS-AX，一种用于脉络膜上腔注射的阿昔替尼注射悬液，目前正在进行 IIb 期临床试验，以治疗湿性年龄相关性黄斑变性。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Clearside Biomedical 更好</li>
<li>股票平均计算器</li>
<li>PayPal 股票：太便宜而无法忽视，太强大而无法错过</li>
<li>如何利用分析师评级进行交易</li>
<li>Progress Software：在 AI 革命的推动下取得进展</li>
<li>深入了解买卖差价</li>
<li>英特尔 - 台湾半导体联盟激发复苏希望</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Clearside Biomedical 吗？</h2>
<p>在你考虑 Clearside Biomedical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Clearside Biomedical 并不在名单上。</p>
<p>虽然 Clearside Biomedical 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Clearside生物医学

CLSDQ

<p>Needham & Company LLC 重申了对 Clearside Biomedical (NASDAQ:CLSD) 的 “买入” 评级，目标价为 4.00 美元，意味着潜在上涨空间为 373.20%。其他分析师也对该股票进行了评级，HC Wainwright 和 Chardan Capital 设定的目标价为 6.00 美元。Clearside Biomedical 的股票开盘价为 0.85 美元，市值为 6521 万美元。该公司报告每股收益为（0.10）美元，超出预期。机构投资者持有该股票的 18.75%，该公司专注于提供眼部疾病的治疗方案</p>

<p>Clearside Biomedical (NASDAQ:CLSD - Get Free Report)'s stock had its &#34;buy&#34; rating reiterated by stock analysts at Needham &amp; Company LLC in a report released on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock. Needham &amp; Company LLC's target price points to a potential upside of 373.20% from the stock's previous close.</p>
<div class="lb-trans"><p>Clearside Biomedical（纳斯达克代码：CLSD - 获取免费报告）的股票在 Needham &amp; Company LLC 发布的一份报告中重申了 “买入” 评级，Benzinga 报道。它们目前对该股票的目标价为 4.00 美元。Needham &amp; Company LLC 的目标价意味着该股票相较于之前的收盘价有 373.20% 的潜在上涨空间。</p>
</div><p>Get <strong>Clearside Biomedical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Clearside Biomedical</strong> 的提醒：</p>
</div><p>CLSD has been the topic of a number of other reports. HC Wainwright restated a &#34;buy&#34; rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Monday, March 31st. StockNews.com lowered shares of Clearside Biomedical from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Tuesday, March 18th. Finally, Chardan Capital reiterated a &#34;buy&#34; rating and issued a $6.00 price target on shares of Clearside Biomedical in a report on Friday, March 28th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Clearside Biomedical currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $5.25.</p>
<div class="lb-trans"><p>CLSD 已经成为其他多份报告的主题。HC Wainwright 在 3 月 31 日的研究报告中重申了 “买入” 评级，并对 Clearside Biomedical 的股票设定了 6.00 美元的目标价。StockNews.com 在 3 月 18 日的研究报告中将 Clearside Biomedical 的股票评级从 “持有” 下调至 “卖出”。最后，Chardan Capital 在 3 月 28 日的报告中重申了 “买入” 评级，并对 Clearside Biomedical 的股票设定了 6.00 美元的目标价。一位分析师对该股票给予了卖出评级，而四位分析师则给予了买入评级。根据 MarketBeat.com 的数据，Clearside Biomedical 目前的共识评级为 “适度买入”，平均目标价为 5.25 美元。</p>
</div><p><strong>View Our Latest Stock Report on CLSD</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 CLSD 股票报告</strong></p>
</div><h2>Clearside Biomedical Stock Performance</h2>
<div class="lb-trans"><h2>Clearside Biomedical 股票表现</h2>
</div><p>Shares of CLSD opened at $0.85 on Tuesday. Clearside Biomedical has a 1 year low of $0.77 and a 1 year high of $1.65. The stock has a market capitalization of $65.21 million, a P/E ratio of -1.88 and a beta of 2.04. The company's fifty day moving average is $0.96 and its two-hundred day moving average is $1.03.</p>
<div class="lb-trans"><p>CLSD 的股票在周二开盘价为 0.85 美元。Clearside Biomedical 的 1 年最低价为 0.77 美元，1 年最高价为 1.65 美元。该股票的市值为 6521 万美元，市盈率为-1.88，贝塔系数为 2.04。公司的 50 日移动平均线为 0.96 美元，200 日移动平均线为 1.03 美元。</p>
</div><p>Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03. The firm had revenue of $0.31 million for the quarter, compared to analysts' expectations of $0.27 million. Sell-side analysts predict that Clearside Biomedical will post -0.48 EPS for the current year.</p>
<div class="lb-trans"><p>Clearside Biomedical（纳斯达克代码：CLSD - 获取免费报告）最近在 3 月 27 日发布了季度财报。该公司报告每股收益（EPS）为-0.10 美元，超出市场共识预期的-0.13 美元，超出幅度为 0.03 美元。该公司本季度的收入为 31 万美元，而分析师预期为 27 万美元。卖方分析师预测 Clearside Biomedical 在当前年度的每股收益将为-0.48 美元。</p>
</div><h2>Hedge Funds Weigh In On Clearside Biomedical</h2>
<div class="lb-trans"><h2>对 Clearside Biomedical 的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the company. Investor s Fiduciary Advisor Network LLC acquired a new stake in Clearside Biomedical during the fourth quarter valued at approximately $32,000. Northern Trust Corp grew its holdings in Clearside Biomedical by 24.0% during the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company's stock valued at $157,000 after purchasing an additional 32,048 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Clearside Biomedical by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company's stock worth $726,000 after purchasing an additional 32,672 shares during the period. Institutional investors and hedge funds own 18.75% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近调整了对该公司的持股。投资者 Fiduciary Advisor Network LLC 在第四季度收购了 Clearside Biomedical 的新股份，价值约为 32,000 美元。Northern Trust Corp 在第四季度将其在 Clearside Biomedical 的持股增加了 24.0%。Northern Trust Corp 目前拥有 165,499 股该公司的股票，价值 157,000 美元，此前在上个季度又购买了 32,048 股。最后，Geode Capital Management LLC 在第四季度将其在 Clearside Biomedical 的股份增加了 4.5%。Geode Capital Management LLC 目前拥有 764,058 股该公司的股票，价值 726,000 美元，此前在该期间又购买了 32,672 股。机构投资者和对冲基金持有该公司 18.75% 的股份。</p>
</div><h2>Clearside Biomedical Company Profile</h2>
<div class="lb-trans"><h2>Clearside Biomedical 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.</p>
<div class="lb-trans"><p>Clearside Biomedical, Inc 是一家生物制药公司，专注于通过脉络膜上腔革命性地输送治疗药物到眼后部。它提供 XIPERE，一种用于治疗葡萄膜炎性黄斑水肿的三氟氯噻吨脉络膜上腔注射悬液。它还开发 CLS-AX，一种用于脉络膜上腔注射的阿昔替尼注射悬液，目前正在进行 IIb 期临床试验，以治疗湿性年龄相关性黄斑变性。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Clearside Biomedical</li>
<li>Stock Average Calculator</li>
<li>PayPal Stock: Too Cheap to Ignore, Too Strong to Miss</li>
<li>How to trade using analyst ratings</li>
<li>Progress Software: Making Progress Driven by the AI Revolution</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Clearside Biomedical 更好</li>
<li>股票平均计算器</li>
<li>PayPal 股票：太便宜而无法忽视，太强大而无法错过</li>
<li>如何利用分析师评级进行交易</li>
<li>Progress Software：在 AI 革命的推动下取得进展</li>
<li>深入了解买卖差价</li>
<li>英特尔 - 台湾半导体联盟激发复苏希望</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Clearside Biomedical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Clearside Biomedical 吗？</h2>
</div><p>Before you consider Clearside Biomedical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Clearside Biomedical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clearside Biomedical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Clearside Biomedical 并不在名单上。</p>
</div><p>While Clearside Biomedical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Clearside Biomedical 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Needham & Company LLC 重申对 Clearside Biomedical (NASDAQ:CLSD) 的 “买入” 评级